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preclinical Alzheimer disease
ABSTRACT
Objective: Diverse autolysosomal proteins were quantified in neurally derived blood exosomes
from patients with Alzheimer disease (AD) and controls to investigate disordered neuronal
autophagy.
Methods: Blood exosomes obtained once from patients with AD (n 5 26) or frontotemporal
dementia (n 5 16), other patients with AD (n 5 20) both when cognitively normal and 1 to 10
years later when diagnosed, and case controls were enriched for neural sources by anti-human
L1CAM antibody immunoabsorption. Extracted exosomal proteins were quantified by ELISAs
and normalized with the CD81 exosomal marker.
Results:Mean exosomal levels of cathepsin D, lysosome-associatedmembrane protein 1 (LAMP-1),
and ubiquitinylated proteins were significantly higher and of heat-shock protein 70 significantly
lower for AD than controls in cross-sectional studies (p # 0.0005). Levels of cathepsin D,
LAMP-1, and ubiquitinylated protein also were significantly higher for patients with AD than
for patients with frontotemporal dementia (p # 0.006). Step-wise discriminant modeling of the
protein levels correctly classified 100% of patients with AD. Exosomal levels of all proteins were
similarly significantly different from those of matched controls in 20 patients 1 to 10 years
before and at diagnosis of AD (p # 0.0003).
Conclusions: Levels of autolysosomal proteins in neurally derived blood exosomes distinguish pa-
tients with AD from case controls and appear to reflect the pathology of AD up to 10 years before
clinical onset. These preliminary results confirm in living patients with AD the early appearance of
neuronal lysosomal dysfunction and suggest that these proteins may be useful biomarkers in
large prospective studies. Neurology® 2015;85:40–47
GLOSSARY
Ab 5 b-amyloid; AD 5 Alzheimer disease; aMCI 5 amnestic mild cognitive impairment; AP 5 preclinical Alzheimer disease;
BSA 5 bovine serum albumin; FTD 5 frontotemporal dementia; HSP70 5 heat-shock protein 70; IRS 5 insulin receptor
substrate; JHSF 5 Jewish Home of San Francisco; LAMP-1 5 lysosome-associated membrane protein 1; MCI 5 mild cog-
nitive impairment;MMSE5Mini-Mental State Examination; NCAM-15 type 1 neural cell adhesion molecule; NIA5 National
Institute on Aging; ROC 5 receiver operating characteristic.
There is an urgent need for biomarkers that accurately detect pathogenic components of Alz-
heimer disease (AD) before appearance of neurologic signs. Early treatments directed to such
targets could limit or reverse neuronal damage and prevent development of overt AD. Recent
analyses of neurally derived plasma exosomal proteins have shown significantly higher levels
of the pathogenic proteins P-T181-tau, P-S396-tau, and b-amyloid (Ab)1-42 in AD than in
case controls.1 Discriminant modeling of these exosomal protein levels correctly classified more
than 96% of patients with AD. Neurally derived plasma exosomal levels of P-T181-tau, P-S396-
tau, and Ab1-42 also were significantly higher in preclinical AD than for controls up to 10 years
before appearance of neurologic signs.1
Altered levels of phosphorylated forms of the insulin receptor proximal signaling protein,
termed insulin receptor substrate (IRS), in neurally derived plasma exosomes supported the
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possibility of brain insulin resistance in AD.2
Neurally derived exosomal levels of insulin
signal-diminishing P-S312-IRS-1 and insulin
signal-enhancing P-panY-IRS-1, and the ratio
of P-S312-IRS-1 to P-panY-IRS-1 (R, an
index of insulin resistance) were significantly
different in AD and type 2 diabetes mellitus
than for case controls. R levels also were sig-
nificantly higher in AD than in type 2 diabetes
mellitus. In 22 patients with AD studied lon-
gitudinally, neurally derived exosomal levels of
P-S312-IRS-1, P-panY-IRS-1, and R were sig-
nificantly different than for controls both 1 to
10 years before and at diagnosis of AD.2
Dystrophic neurons showing segmental dis-
tensions with increased numbers of lysosomes
and autophagic vacuoles are prominent in AD,
but protein biodegradation in resultant autoly-
sosomes fails progressively.3 Upregulation and
then failure of neuronal autophagic-lysosomal
systems in AD causes lysosomal components
to leak into neural extracellular fluid around
plaques and into the CSF.4,5 Although fusion
of exosome-containing multivesicular bodies
with lysosomes has been considered a mecha-
nism for elimination of unnecessary exosomal
proteins, autolysosomal dysfunction of neu-
rons in AD may result in addition of lysosomal
proteins to exosomal cargo for facilitation of
their removal from neurons.3,6
We now examine extracts of neurally derived
plasma exosomes from patients with AD, pa-
tients with frontotemporal dementia (FTD),
and cognitively normal matched controls for
differences in quantities of distinct types of
lysosome-associated proteins. Results support
there being major abnormalities of neural cell
autophagic-lysosomal pathways in AD.
METHODS Experimental design and patient evaluation.
For cross-sectional studies, we retrospectively identified 26
patients with amnestic mild cognitive impairment (aMCI, n 5
18) or mild to moderate dementia (n 5 8) from AD, who had
donated blood once in the Clinical Research Unit of the National
Institute on Aging (NIA), Baltimore, MD, or at the Jewish Home
of San Francisco (JHSF), CA (table 1). For longitudinal studies,
20 additional patients with AD were identified retrospectively
based on their provision of blood twice at the Mayo Clinic or
the University of Kentucky, first when cognitively intact and later
at diagnosis of AD (table 1). Intervals between the 2 blood
samples (number of patients) were 1 to 5 years (7) and 6 to 10
years (13). Each patient in both cross-sectional and longitudinal
groups had mental status testing and an MRI, and some had
measurements of CSF Ab1-42, total tau, and P-T181-tau.
Cognitively normal control participants (AC group) were from
the NIA or JHSF and were matched to characteristics of the
patients with AD in cross-sectional studies or preclinical (AP)
patients in longitudinal studies. Samples from patients in the
longitudinal study were analyzed without knowledge of the
clinical data.
Table 1 Characteristics of patients and control participants
Diagnosis
Total Neurologic subgroup
No. M/F
Age, y,
mean 6 SD
(range) No.
MMSE score,
mean 6 SEM No.
MMSE score,
mean 6 SEM
A. Cross-sectional studies MCI Dementia
AD 26 13/13 75.4 6 7.85 (62–92) 18 28.0 6 0.40 8 22.5 6 1.48a
AC 26 13/13 75.8 6 7.91 (62–92) 0 0
Mild dementia Moderate dementia
FTD 16 12/4 63.1 6 8.79 (48–79) 9 26.7 6 0.73 7 15.0 6 3.65b
FTC 16 12/4 63.7 6 7.43 (48–79) 0 0
B. Longitudinal studies MCI Dementia
AP 20 10/10 74.0 6 5.95 (59–93) 0 29.1 6 0.26c 0 29.0 6 0.36a
AD 20 10/10 80.1 6 6.21 (60–100) 9 25.8 6 1.30 11 21.6 6 1.07c
AC 20 10/10 73.8 6 5.93 (59–93) 0 0
Abbreviations: AC 5 Alzheimer normal control; AD 5 Alzheimer disease; AP 5 preclinical Alzheimer disease; FTC 5 frontotemporal normal control; FTD 5
frontotemporal dementia; MCI 5 mild cognitive impairment; MMSE 5 Mini-Mental State Examination.
The significance of differences in values between the MCI/mild dementia and dementia/moderate dementia (1A) groups and between the respective AP and
AD groups as well as AD subgroups (1B) were calculated by an unpaired t test.
ap , 0.001.
bp , 0.01.
cp , 0.05.
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Patients were classified as having aMCI according to Petersen
criteria and had Clinical Dementia Rating global scores of 0.5.7,8
Those with probable AD and mild to moderate dementia were
diagnosed by Dubois criteria or for University of Kentucky pa-
tients by NINCDS-ADRDA (National Institute of Neurological
and Communicative Disorders and Stroke–Alzheimer’s Disease
and Related Disorders Association) criteria and had Clinical
Dementia Rating global scores of at least 1.0.9,10 A CSF level of
Ab1-42,192 pg/mL supported a diagnosis of AD.11Mini-Mental
State Examination (MMSE) and the Alzheimer’s Disease Assess-
ment Scale–cognitive subscale were conducted as described.12,13
Twenty-four of the 26 cross-sectional patients with AD were taking
an acetyl-cholinesterase inhibitor and/or memantine, and 5 were on
antidepressant medications.
Sixteen patients with the behavioral variant of FTD were eval-
uated at the Memory and Aging Center of the Department of
Neurology of the University of California, San Francisco. Their
diagnosis and assignment to mild or moderate dementia groups
(table 1) were based on standard clinical and mental status crite-
ria, including discriminant analyses of neuropsychiatric and other
elements that distinguish FTD from AD.14,15 Seven of the pa-
tients with FTD were receiving an antidepressant, 2 were taking
an acetyl-cholinesterase inhibitor, and one was on memantine.
Cognitively normal control participants (FTC) were matched to
patients with FTD as for AC controls.
Blood and CSF sampling of patients and control participants.
Each participant studied and some patient designates signed a
consent form approved with the protocol at each institution.
Thirty milliliters of venous blood was drawn into 1 mL of saline
with ethylenediaminetetraacetic acid or heparin, incubated for
10 minutes at room temperature, and centrifuged for 15 minutes
at 2,500g.1 Plasma was stored in 0.5-mL aliquots at280°C. CSF
levels of total tau, P-T181-tau, and Ab1-42 were quantified by
Luminex xMAP technology using Innogenetics INNO-BIA Alz
Bio3 kits (Innogenetics, Ghent, Belgium).
Isolation of exosomes from plasma for extraction and
ELISA quantification of exosome proteins. One-half millili-
ter of plasma was incubated with thromboplastin-D (Fisher
Scientific, Inc., Hanover Park, IL) followed by addition of
calcium- and magnesium-free Dulbecco balanced salt solution
(DBS22) with protease inhibitor cocktail (Roche Applied
Sciences, Inc., Indianapolis, IN) and phosphatase inhibitor
cocktail (Pierce Halt, Thermo Scientific, Inc., Rockford, IL).1,2
After centrifugation, supernates were incubated with ExoQuick
exosome precipitation solution (EXOQ; System Biosciences, Inc.,
Mountain View, CA) and resultant suspensions centrifuged at
1,500g for 30 minutes at 4°C. Each pellet was resuspended in
250 mL of distilled water with inhibitor cocktails for
immunochemical enrichment of exosomes from neural sources.1
Exosome suspensions were incubated with 2 mg of mouse
anti-human CD171 (L1CAM neural adhesion protein) biotiny-
lated antibody (clone 5G3; eBioscience, San Diego, CA) in 50mL
of 3% bovine serum albumin (BSA) for 60 minutes at 20°C
followed by addition of 10 mL of Streptavidin-Plus UltraLink
resin (Pierce-Thermo Scientific, Inc.) in 40 mL of 3% BSA.1,2
After centrifugation, pellets were resuspended in 50 mL of 0.05
M glycine-HCl (pH 3.0), incubated at 4°C for 10 minutes,
mixed with 50 mL of 3% BSA, and recentrifuged. Each supernate
in a new Eppendorf tube received 5 mL of 1 M Tris-HCl (pH
8.0) followed by 0.40 mL of M-PER mammalian protein extrac-
tion reagent (Thermo Scientific, Inc.) containing protease and
phosphatase inhibitors, mixed and stored at 280°C.
Exosome proteins were quantified by human-specific ELISAs
for total ubiquitin (FIVEphoton Biochemicals, San Diego, CA),
lysosome-associated membrane protein 1 (LAMP-1) (USBiological
Life Sciences, Salem, MA), heat-shock protein 70 (HSP70; high
sensitivity) (Enzo Life Sciences, Farmingdale, NY), cathepsin D
(EMD Millipore Corp., Billerica, MA), neuron-specific enolase
(R&D Systems, Inc., Minneapolis, MN), neurofilament light chain
(American Research Products, Waltham, MA; Cusabio), type
1 neural cell adhesion molecule (NCAM-1) (RayBiotech, Norcross,
GA), and tetraspanin exosome marker human CD81 (American
Research Products, Cusabio) with verification of the CD81 antigen
standard curve using human purified recombinant CD81 antigen
(OriGene Technologies, Inc., Rockville, MD), according to sup-
pliers’ directions. The mean value for all determinations of CD81
in each assay group was set at 1.00 and the relative values for each
sample used to normalize their recovery. Evidence for enrichment
of exosomes from neural sources comes from comparison of the
levels of known neural markers relative to the CD81 exosome
marker after initial precipitation and after immuno-isolation by
anti-L1CAM antibody absorption (table e-1 on the Neurology®
Web site at Neurology.org). Although there are differences in exo-
somal levels of most neural markers between patients with AD and
controls, immune-specific enrichment increased the levels of all
neural markers in both groups by 8- to 13-fold.
Statistical analyses. The statistical significance of differences
between means for cross-sectional patient groups and between
each patient group and their respective control group was
determined with an unpaired t test including a Bonferroni
correction (GraphPad Prism 6, La Jolla, CA). Discriminant
classifier analyses were conducted by the Wilks L method to
assess the performance of each exosomal protein and the
combined set in patient classification, as described.1 Receiver
operating characteristic (ROC) analyses were conducted under
the nonparametric distribution assumption for standard error of
area to determine the performance of classifier models (SPSS
version 21.0; IBM Corp., Armonk, NY).1 For longitudinal
analyses, the significance of differences between serial values for
patients with AD taken before and after onset of aMCI or
dementia was calculated with a paired t test (GraphPad).
RESULTS Patient characteristics. More of the patients
with AD in cross-sectional studies had aMCI than
dementia and the latter group had significantly lower
MMSE scores than the former (p , 0.001) (table
1A). The MMSE scores for patients with AD who
had dementia in the longitudinal group also were
significantly lower than those with aMCI (table 1B).
MMSE scores for both neurologic subgroups of
patients with AD in the longitudinal study were
significantly higher in their preclinical phase (AP)
than after development of AD (table 1B). The 16
patients with FTD were a younger group than those
with AD and had more with mild dementia than
moderate dementia, with the latter group having
significantly lower MMSE scores (p, 0.01) (table 1A).
Exosomal protein levels in cross-sectional studies and
relationship to severity of cognitive loss.The aspartyl en-
doproteinase cathepsin D normally is localized in lyso-
somes and endosomes in several types of neural cells,
where it cleaves diverse proteins.16–18 Neuronal lyso-
somal proteolytic dysfunction in AD results in massive
accumulation of cathepsin D–rich autolysosomes and
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elevated secretion of cathepsin D, which we hypoth-
esized was exosome-associated.6,19,20 Exosomal levels
of cathepsin D for the patients with AD in cross-
sectional studies were 17.7 6 0.80 ng/mL (mean 6
SEM), which were significantly higher than the level
of 8.356 0.27 ng/mL for the control AC participants
(p , 0.0001) (figure 1). Cathepsin D levels for
patients with FTD of 12.8 6 0.75 ng/mL were
significantly lower than those for patients with AD
(p 5 0.0001), but were significantly higher than
those of 6.23 6 0.15 ng/mL for their FTC control
group (p , 0.0001).
The lysosomal outer membrane proteins, termed
types 1 and 2 lysosome-associated membrane proteins
(LAMP-1 and LAMP-2), associate with and stabilize
polypeptide translocational systems, such as trans-
porter associated with antigen processing like
(TAPL).21 If the autophagic-lysosomal dysfunction
of neurons in AD results in exosomal uptake of lyso-
somal membrane proteins as well as lysosomal granule
cathepsin D, we hypothesized that LAMP-1 levels are
elevated in neurally derived plasma exosomes from
patients with AD as contrasted with those from AC
controls. Exosomal levels of LAMP-1 for the patients
with AD in cross-sectional studies were 1,8086 204
pg/mL (mean 6 SEM), which were significantly
higher than the level of 946 6 119 pg/mL for the
control AC participants (p 5 0.00051) (figure 1).
The LAMP-1 levels for the patients with FTD of
1,071 6 62.7 pg/mL were significantly lower than
those of the patients with AD (p5 0.0058) and were
not significantly different than those of 1,1476 88.9
pg/mL for their FTC control group (p 5 0.4892).
Ubiquitinylation and elimination from brain of
some neuropathic proteins by proteosomal and
autophagic-lysosomal systems are abnormal in AD.3
Neural localization of proteins with critical functions,
such as synaptic transmission, and efficient sorting of
proteins into exosome-containing multivesicular bod-
ies both require precise ubiquitin labeling, which is
abnormal in AD.22–24 To examine exosomal conse-
quences of neural protein ubiquitinylation defects
in AD, total ubiquitin-labeled proteins were quanti-
fied in neural-derived plasma exosomes. Exosomal
levels of ubiquitinylated proteins for the patients with
AD in cross-sectional studies were 4776 25.4 pg/mL
(mean 6 SEM), which were significantly higher than
the level of 225 6 10.1 pg/mL for control AC partic-
ipants (p , 0.0001) (figure 1). The levels of ubiquiti-
nylated proteins for the patients with FTD of 255 6
11.5 pg/mL were significantly lower than those of the
patients with AD (p , 0.0001), but were not
Figure 1 Levels of plasma exosomal proteins in patients with AD, FTD, and cognitively normal case controls
The horizontal line in each cluster here and in figure 2 depicts the mean for that set. AC 5 Alzheimer normal control; AD 5
Alzheimer disease; FTC5 frontotemporal normal control; FTD5 frontotemporal dementia; HSP705 heat-shock protein 70;
LAMP-1 5 lysosome-associated membrane protein 1.
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significantly different than those of 2286 8.53 pg/mL
for their FTC control group (p 5 0.0726).
The HSP70 family of protein chaperones exhibits
diverse effects on configuration, oligomerization, trans-
membrane transport, and survival of many proteins,
and promotes removal of damaged proteins.25,26
HSP70 proteins also prevent abnormal alterations in
lysosomal permeability and inhibit apoptosis.27,28
HSP70 release from some cells is largely dependent on
exosome secretion, rather than the common secretory or
lipid raft-mediated pathways, and the level of HSP70 in
exosomal cargo is increased by cellular stress.29 Levels of
HSP70 in neural-derived plasma exosomes were quan-
tified to identify deficiencies that might diminish auto-
lysosomal clearance of neuropathic proteins in AD.
Exosomal levels of HSP70 for the patients with AD
in cross-sectional studies were 246 6 18.0 pg/mL
(mean 6 SEM), which were significantly lower than
the level of 394 6 15.2 pg/mL for the control AC
participants (p , 0.0001) (figure 1). The levels of
HSP70 for the patients with FTD of 165 6 4.39
pg/mL were significantly lower than those of the
patients with AD (p 5 0.0012) and those of
429 6 15.6 pg/mL for their FTC control group
(p , 0.0001). Exosomal levels of cathepsin D,
LAMP-1, ubiquitinylated proteins, and HSP70 for
patients with AD in the cross-sectional studies were
the same for the mild cognitive impairment (MCI)
and dementia neurologic subgroups (table 2). Fur-
thermore, there were no differences in exosomal lev-
els of any of the autolysosomal proteins in cross-
sectional or longitudinal studies between patients
with AD who had APOE 4/4 genotype (5) or x/4
genotype (9) and those without a type 4 APOE allele.
Stepwise discriminant classification of AD vs AC
incorporated cathepsin D, then ubiquitinylated pro-
teins, and finally HSP70, but not LAMP-1 (figure
e-1). ROC curves of AD vs AC showed an area under
the curve of 1.0 for both cathepsin D and composite
scores from the final model with correct classification
of 100% of the patients with AD. Similar ROC anal-
yses correctly classified 100% of patients with FTD vs
FTC controls and 95.8% of patients with AD vs pa-
tients with FTD.
Longitudinal studies of exosomal protein levels in
conversions from preclinical to overt AD. The exosomal
levels of cathepsin D, LAMP-1, ubiquitinylated
proteins, and HSP70 for the longitudinal AC control
group were indistinguishable from those of the cross-
sectional AC control group at 8.50 6 0.36 ng/mL
(mean 6 SEM), 1,035 6 119 pg/mL, 206 6 7.46
pg/mL, and 3926 14.2 pg/mL, respectively (figure 2).
The exosomal levels of cathepsin D, LAMP-1,
ubiquitinylated proteins, and HSP70 for the AD
group at time of diagnosis of MCI or dementia
were 19.0 6 0.70 ng/mL, 2,080 6 257 pg/mL,
347 6 13.9 pg/mL, and 250 6 11.8 pg/mL,
respectively, which were significantly higher or for
HSP70 lower than corresponding values for the
AC group (p , 0.0001 for all, except LAMP-1
where p 5 0.0003). For the preclinical AP group,
1 to 10 years before diagnosis of AD, exosomal
levels of the same proteins were 18.4 6 0.68 ng/
mL, 2,638 6 354 pg/mL, 364 6 13.9 pg/mL, and
244 6 16.4 pg/mL, respectively, which were
significantly different from those of the AC
control group (p , 0.0001 for all) (figure 2).
There were no significant differences between any
of the exosomal protein levels of the preclinical AP group
and those of the AD group at neurologic conversion.
Finally, there were no distinctions between AP or AD
exosomal protein levels for those patients who converted
to MCI as contrasted with dementia or for those who
converted neurologically in 1 to 5 years as contrasted
with 6 to 10 years.
DISCUSSION The results of analyses of neural-
derived plasma exosome proteins derived from
lysosomes and related cellular organelles increase
our understanding of lysosomal dysfunction in AD
and may provide useful biomarkers for recognizing
preclinical AD. The levels of cathepsin D, LAMP-1,
and ubiquitinylated proteins all were significantly
higher and those of HSP70 significantly lower in
neural-derived plasma exosomes from AD plasmas
than from control plasmas and there was no overlap
in values for cathepsin D (figure 1). Thus,
autophagocytic-lysosomal dysfunction in AD results
in increased cargo levels per exosome of the intrinsic
lysosomal components cathepsin D and LAMP-1, as
well as ubiquitinylated proteins destined for
elimination in autolysosomes, but lower cargo levels
of cytosolic HSP70 that normally is secreted
predominantly in exosomes. AD was statistically
distinguished from FTD by levels of all these
proteins, but differences between FTD and FTC
were significant only for cathepsin D and HSP70.
Furthermore, none of the lysosome-related neural-
derived plasma exosome proteins distinguished AD
Table 2 Levels of serum exosome proteins in relation to severity of dementia
in AD
Group No. Cathepsin D LAMP-1 Ubiquitin HSP70
AD, MCI 27 18.2 6 0.73 1,943 6 214 446 6 26.3 239 6 17.2
AD, dementia 19 18.6 6 0.93 1,911 6 252 377 6 19.2 260 6 11.9
Abbreviations: AD 5 Alzheimer disease; HSP70 5 heat-shock protein 70; LAMP-1 5
lysosome-associated membrane protein 1; MCI 5 mild cognitive impairment.
All values are mean 6 SEM, pg/mL, except for cathepsin D, which is ng/mL. None of the
differences between values for the MCI and dementia groups were significant.
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from FTD as well as P-S396-tau, where there was no
overlap.1
Longitudinal studies of lysosome-related neural-
derived plasma exosomal proteins showed significant
differences in levels between those of controls and of
patients with AD both at their preclinical phase 1 to
10 years before diagnosis (AP) and when manifesting
clinically apparent signs of AD (figure 2). None of the
exosomal levels of lysosome-related proteins was sig-
nificantly higher in AD than in the preclinical phase
(figure 2), as for neural-derived plasma exosome levels
of proteins implicated in pathogenesis of AD, except
Ab1-42, and of abnormally phosphorylated forms of
IRS.1,2
The assumption that levels of lysosome-related
neurally derived plasma exosomal proteins reflect
their relative concentrations in neural cells is based
on several findings. Support for their neural source
comes from observing .95% cross-binding of neu-
rally enriched exosomes by anti-NCAM-1 and anti-
L1CAM antibodies, and 8- to 13-fold mean increases
by neural enrichment in content of multiple neural
markers relative to total precipitated plasma exosomes
(table e-1). The number and size distribution of
neural-derived exosomes isolated from a given volume
of plasma have been the same for patients with AD
and AC controls in our limited series.1 Thus, differ-
ences between patients with AD and AC controls in
neurally derived plasma exosomal levels of proteins
implicated in AD pathogenesis presumably reflect
principally those of cargo per exosome.1,2 However,
other variables that affect exosome biogenesis, secre-
tion, and cargo content must be examined in much
larger numbers of patients.
Exosome-containing multivesicular bodies nor-
mally either fuse with the plasma membrane for exo-
some secretion or dock with lysosomes for exosome
biodegradation, but in AD appear to import cargo
from dysfunctional autolysosomes for transport to
the extracellular space.1,6 Neural cellular stress at some
stages of AD thereby increase amounts of proteins per
exosome, as for stressed leukocyte-derived exosome
content of HSP70.29 Furthermore, lysosomal dys-
function induced by some neurotoxic proteins may
increase the exosomal cargo of proteins, as we have
found (table e-1).30 These diverse mechanisms of
autophagic-lysosomal dysfunction in AD provide
new targets for potentially therapeutic agents and
Figure 2 Sequential levels of plasma exosomal proteins in patients with ADmeasured first at a time of normal
cognition (preclinical, AP) and later at the time of development of aMCI or dementia (AD), as
contrasted with cognitively normal control participants (AC) matched to individuals in their
preclinical phase
AC 5 Alzheimer normal control; AD 5 Alzheimer disease; aMCI 5 amnestic mild cognitive impairment; AP 5 preclinical
Alzheimer disease; FTC5 frontotemporal normal control; FTD5 frontotemporal dementia; HSP705 heat-shock protein 70;
LAMP-1 5 lysosome-associated membrane protein 1.
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the proteins are useful biomarkers for large prospec-
tive studies.
Numerous problems inherent in retrospective stud-
ies of small numbers of carefully selected patients sug-
gest that conclusions of the preliminary investigations
here reported may be modified by results of larger pro-
spective analyses. All of our control groups excluded
subjects with a family history of AD. The patients in
the longitudinal set were selected based on availability
of a paired earlier plasma sample for analysis, which re-
stricts assessment of predictive accuracy. Many aspects
of assay method reproducibility have met accepted cri-
teria, but full validation series are still in progress.
Nonetheless, quantification of 3 other clusters of neu-
ral derived exosome proteins has shown the same
capacity as that reported here for distinguishing neuro-
degenerative diseases from matched controls cross-
sectionally and longitudinally.1,2,31
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It’s Time to Plan for ICD-10, and the AAN Can Help
All health care providers are required to transition to ICD-10 on October 1, 2015. Claims for serv-
ices performed on or after this date with an ICD-9 code will not be processed and payments will be
delayed. The AAN provides information and resources to help you make this a smooth transition,
and has partnered with Complete Practice Resources to provide you with an affordable online pro-
ject management tool to help walk you through each phase of the necessary preparation to ensure
you’re ready. Learn more at AAN.com/view/ICD10 and start your transition today!
Neurology® Genetics Call For Papers
Neurology: Genetics is an open access, online only journal that
will provide neurologists with outstanding original contribu-
tions that elucidate the role of genetic and epigenetic variation
in diseases and biological traits of the central and peripheral
nervous system. We welcome all submissions. For more infor-
mation on how to submit, visit http://www.neurology.org/site/
gen/gen2.xhtml.
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